Pier Capital, LLC Halozyme Therapeutics, Inc. Transaction History

Pier Capital, LLC

$670 Million
Q3 2024

A detailed history of Pier Capital, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Pier Capital, LLC holds 144,850 shares of HALO stock, worth $6.61 Million. This represents 1.24% of its overall portfolio holdings.

Number of Shares

144,850

Previous 220,447 34.29%

Holding current value

$6.61 Million

Previous $11.5 Million 28.21%

% of portfolio

1.24%

Previous 1.8%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$51.3 - $64.42 $3.88 Million - $4.87 Million	-75,597 Reduced 34.29%	144,850 $8.29 Million
Q2 2024 Aug 07, 2024	SELL	$37.81 - $52.4 $82,614 - $114,494	-2,185 Reduced 0.98%	220,447 $11.5 Million
Q1 2024 May 02, 2024	BUY	$33.68 - $41.95 $3.14 Million - $3.91 Million	93,153 Added 71.94%	222,632 $9.06 Million
Q4 2023 Feb 15, 2024	SELL	$33.32 - $42.1 $80,834 - $102,134	-2,426 Reduced 1.84%	129,479 $4.79 Million
Q3 2023 Nov 14, 2023	SELL	$36.46 - $44.03 $149,048 - $179,994	-4,088 Reduced 3.01%	131,905 $5.04 Million
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $1.45 Million - $1.86 Million	48,035 Added 54.61%	135,993 $4.91 Million
Q1 2023 May 10, 2023	SELL	$32.86 - $55.7 $2.74 Million - $4.64 Million	-83,366 Reduced 48.66%	87,958 $3.36 Million
Q4 2022 Feb 15, 2023	SELL	$40.06 - $59.44 $45,147 - $66,988	-1,127 Reduced 0.65%	171,324 $9.75 Million
Q3 2022 Nov 15, 2022	BUY	$38.53 - $51.78 $6.64 Million - $8.93 Million	172,451 New	172,451 $6.82 Million

Others Institutions Holding HALO

# of Institutions

542

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.36B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pier Capital, LLC with notifications on news.

Account